Bio€quity is the event for all financial dealmakers looking for hot life science investments and for those in the industry aiming to learn more about investments, local vs global markets and strategic growth.
This year’s BioEquity Europe, arranged in Copenhagen, celebrated its 17th meeting and showcased several interesting investment opportunities, company presentations and networking gatherings. The program also included a plenary session focusing on what’s needed in Europe to get more US investor representation. The session brought together US managers who control more than $30 billion in capital to share notes on what is required to get more US investor representation in Europe, and what´s needed for them to invest in European biotechs. There was also case studies on successful cross border investment and speakers included James Healy, General Partner at Sofinnova Ventures, Chau Khuong, Private Equity Partner at OrbiMed and Kurt von Emster, Managing partner at Abingworth.
There was also discussions about big pharma/VC worlds – an evolving relationship. The workshop explored the dynamics between big pharma and the venture community and it explored how young companies can strategically position their growth and interactions with both groups. It also examined whether corporate VCs have the assets and the ability to fill a void in the private arena that has been created by an exodus of crossover investors.
In addition there was a session about listing strategies for biotech companies, locally vs globally, a CEO boot camp and experts took a closer look at science, if it has become more investable and what it will take beyond the money to turn these concepts into products for patients.